{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T19:29:43Z","timestamp":1770751783767,"version":"3.50.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2011,9,13]],"date-time":"2011-09-13T00:00:00Z","timestamp":1315872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2011,9,13]],"date-time":"2011-09-13T00:00:00Z","timestamp":1315872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1007\/s10637-011-9744-z","type":"journal-article","created":{"date-parts":[[2011,9,12]],"date-time":"2011-09-12T09:59:17Z","timestamp":1315821557000},"page":"2035-2045","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Therapeutic reactivation of mutant p53 protein by quinazoline derivatives"],"prefix":"10.1007","volume":"30","author":[{"given":"Hamish S.","family":"Sutherland","sequence":"first","affiliation":[]},{"given":"In Young","family":"Hwang","sequence":"additional","affiliation":[]},{"given":"Elaine S.","family":"Marshall","sequence":"additional","affiliation":[]},{"given":"Brent S.","family":"Lindsay","sequence":"additional","affiliation":[]},{"given":"William A.","family":"Denny","sequence":"additional","affiliation":[]},{"given":"Catherine","family":"Gilchrist","sequence":"additional","affiliation":[]},{"given":"Wayne R.","family":"Joseph","sequence":"additional","affiliation":[]},{"given":"Debra","family":"Greenhalgh","sequence":"additional","affiliation":[]},{"given":"Emma","family":"Richardson","sequence":"additional","affiliation":[]},{"given":"Philip","family":"Kestell","sequence":"additional","affiliation":[]},{"given":"Angela","family":"Ding","sequence":"additional","affiliation":[]},{"given":"Bruce C.","family":"Baguley","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2011,9,13]]},"reference":[{"key":"9744_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/358015a0","volume":"358","author":"DP Lane","year":"1992","unstructured":"Lane DP (1992) Cancer. p53, guardian of the genome. Nature 358:15\u201316","journal-title":"Nature"},{"key":"9744_CR2","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S0092-8674(00)81871-1","volume":"88","author":"AJ Levine","year":"1997","unstructured":"Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88:323\u2013331","journal-title":"Cell"},{"key":"9744_CR3","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nrm1546","volume":"6","author":"S Sengupta","year":"2005","unstructured":"Sengupta S, Harris CC (2005) p53: traffic cop at the crossroads of DNA repair and recombination. Nat Rev Mol Cell Biol 6:44\u201355","journal-title":"Nat Rev Mol Cell Biol"},{"key":"9744_CR4","doi-asserted-by":"publisher","first-page":"22473","DOI":"10.1074\/jbc.M109.081042","volume":"285","author":"J Han","year":"2010","unstructured":"Han J, Goldstein LA, Hou W, Gastman BR, Rabinowich H (2010) Regulation of mitochondrial apoptotic events by p53-mediated disruption of complexes between antiapoptotic Bcl-2 members and Bim. J Biol Chem 285:22473\u201322483","journal-title":"J Biol Chem"},{"key":"9744_CR5","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/nature05529","volume":"445","author":"W Xue","year":"2007","unstructured":"Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, Cordon-Cardo C, Lowe SW (2007) Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445:656\u2013660","journal-title":"Nature"},{"key":"9744_CR6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S0378-1119(01)00696-5","volume":"277","author":"C Cadwell","year":"2001","unstructured":"Cadwell C, Zambetti GP (2001) The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth. Gene 277:15\u201330","journal-title":"Gene"},{"key":"9744_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrclinonc.2010.174","volume":"8","author":"CF Cheok","year":"2010","unstructured":"Cheok CF, Verma CS, Baselga J, Lane DP (2010) Translating p53 into the clinic. Nature Rev Clin Oncol 8:25\u201337","journal-title":"Nature Rev Clin Oncol"},{"key":"9744_CR8","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/nrc2763","volume":"9","author":"CJ Brown","year":"2009","unstructured":"Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP (2009) Awakening guardian angels: drugging the p53 pathway. Nature Rev Cancer 9:862\u2013873","journal-title":"Nature Rev Cancer"},{"key":"9744_CR9","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1126\/science.286.5449.2507","volume":"286","author":"BA Foster","year":"1999","unstructured":"Foster BA, Coffey HA, Morin MJ, Rastinejad F (1999) Pharmacological rescue of mutant p53 conformation and function. Science 286:2507\u20132510","journal-title":"Science"},{"key":"9744_CR10","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1172\/JCI32481","volume":"117","author":"X Tang","year":"2007","unstructured":"Tang X, Zhu Y, Han L, Kim AL, Kopelovich L, Bickers DR, Athar M (2007) CP-31398 restores mutant p53 tumor suppressor function and inhibits UVB-induced skin carcinogenesis in mice. J Clin Invest 117:3753\u20133764","journal-title":"J Clin Invest"},{"key":"9744_CR11","doi-asserted-by":"publisher","first-page":"3658","DOI":"10.1172\/JCI34251","volume":"117","author":"WS El Deiry","year":"2007","unstructured":"El Deiry WS (2007) Targeting mutant p53 shows promise for sunscreens and skin cancer. J Clin Invest 117:3658\u20133660","journal-title":"J Clin Invest"},{"key":"9744_CR12","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1038\/sj.onc.1205362","volume":"21","author":"TM Rippin","year":"2002","unstructured":"Rippin TM, Bykov VJ, Freund SM, Selivanova G, Wiman KG, Fersht AR (2002) Characterization of the p53-rescue drug CP-31398 in vitro and in living cells. Oncogene 21:2119\u20132129","journal-title":"Oncogene"},{"key":"9744_CR13","doi-asserted-by":"publisher","first-page":"8233","DOI":"10.1038\/sj.onc.1207198","volume":"22","author":"J Wischhusen","year":"2003","unstructured":"Wischhusen J, Naumann U, Ohgaki H, Rastinejad F, Weller M (2003) CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death. Oncogene 22:8233\u20138245","journal-title":"Oncogene"},{"key":"9744_CR14","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1016\/S0968-0896(03)00142-1","volume":"11","author":"VJ Ram","year":"2003","unstructured":"Ram VJ, Farhanullah, Tripathi BK, Srivastava AK (2003) Synthesis and antihyperglycemic activity of suitably functionalized 3H-quinazolin-4-ones. Bioorg Med Chem 11:2439\u20132444","journal-title":"Bioorg Med Chem"},{"key":"9744_CR15","unstructured":"Coffey HA, Connell RD, Foster BA, Rastinejad F. Methods and compositions using hydrophobic group- and cationic group-containing compounds for restoring conformational stability of a protein of the p53 family. (PCT Int. Appl.CODEN: PIXXD2 WO 2000032175 A2 20000608 CAN 133:26844 AN 2000:383903 CAPLUS), 1\u201376. 2000"},{"key":"9744_CR16","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3727\/096504001108747620","volume":"12","author":"J Parmar","year":"2000","unstructured":"Parmar J, Marshall ES, Charters GA, Holdaway KM, Shelling AN, Baguley BC (2000) Radiation-induced cell cycle delays and p53 status of early passage melanoma cell lines. Oncol Res 12:149\u2013155","journal-title":"Oncol Res"},{"key":"9744_CR17","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/0959-8049(94)00472-H","volume":"31A","author":"BC Baguley","year":"1995","unstructured":"Baguley BC, Marshall ES, Whittaker JR, Dotchin MC, Nixon J, McCrystal MR, Finlay GJ, Matthews JH, Holdaway KM, van Zijl P (1995) Resistance mechanisms determining the in vitro sensitivity to paclitaxel of tumour cells cultured from patients with ovarian cancer. Eur J Cancer 31A:230\u2013237","journal-title":"Eur J Cancer"},{"key":"9744_CR18","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1038\/sj.bjc.6605642","volume":"102","author":"P Workman","year":"2010","unstructured":"Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham DA, Glennie MJ, Kelland LR, Robinson V, Stratford IJ, Tozer GM, Watson S, Wedge SR, Eccles SA (2010) Guidelines for the welfare and use of animals in cancer research. Br J Cancer 102:1555\u20131577","journal-title":"Br J Cancer"},{"key":"9744_CR19","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s00285-003-0254-2","volume":"49","author":"B Basse","year":"2004","unstructured":"Basse B, Baguley BC, Marshall ES, Joseph WR, van Brunt B, Wake GC, Wall DJN (2004) Modelling cell death in human tumour cell lines exposed to the anticancer drug paclitaxel. J Math Biol 49:329\u2013357","journal-title":"J Math Biol"},{"key":"9744_CR20","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1126\/science.1092472","volume":"303","author":"LT Vassilev","year":"2004","unstructured":"Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303:844\u2013848","journal-title":"Science"},{"key":"9744_CR21","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1021\/jm00134a009","volume":"24","author":"BC Baguley","year":"1981","unstructured":"Baguley BC, Denny WA, Atwell GJ, Cain BF (1981) Potential antitumor agents. 34. Quantitative relationships between DNA binding and molecular structure for 9-anilinoacridines substituted in the anilino ring. J Med Chem 24:170\u2013177","journal-title":"J Med Chem"},{"key":"9744_CR22","doi-asserted-by":"crossref","unstructured":"Denny WA, Baguley BC (1994) New anticancer acridines. In: Neidle S, Waring MJ (eds) Molecular aspects of anticancer drug-DNA interaction. London, pp 270\u2013311","DOI":"10.1007\/978-1-349-13330-7_7"},{"key":"9744_CR23","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1073\/pnas.81.5.1361","volume":"81","author":"EM Nelson","year":"1984","unstructured":"Nelson EM, Tewey K, Liu LF (1984) Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4\u2032-(9-acridinylamino)-methanesulfon-m-anisidide. Proc Natl Acad Sci U S A 81:1361\u20131365","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9744_CR24","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1093\/jnci\/82.8.662","volume":"82","author":"GJ Finlay","year":"1990","unstructured":"Finlay GJ, Baguley BC, Snow K, Judd W (1990) Multiple patterns of resistance of human leukemia cell sublines to amsacrine analogues. J Natl Cancer Inst 82:662\u2013667","journal-title":"J Natl Cancer Inst"},{"key":"9744_CR25","doi-asserted-by":"crossref","unstructured":"Drummond CJ, Finlay GJ, Broome L, Marshall ES, Richardson E, Baguley BC (2010) Action of SN 28049, a new DNA binding topoisomerase II-directed antitumour drug: comparison with doxorubicin and etoposide. Invest New Drugs in press","DOI":"10.1007\/s10637-010-9473-8"},{"key":"9744_CR26","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/nature03482","volume":"434","author":"J Bartkova","year":"2005","unstructured":"Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, Orntoft T, Lukas J, Bartek J (2005) DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434:864\u2013870","journal-title":"Nature"},{"key":"9744_CR27","first-page":"1","volume":"6","author":"BC Baguley","year":"1991","unstructured":"Baguley BC (1991) DNA intercalating anti-tumour agents. Anticancer Drug Des 6:1\u201335","journal-title":"Anticancer Drug Des"},{"key":"9744_CR28","doi-asserted-by":"publisher","first-page":"14626","DOI":"10.1074\/jbc.M610514200","volume":"282","author":"M Sasaki","year":"2007","unstructured":"Sasaki M, Nie L, Maki CG (2007) MDM2 binding induces a conformational change in p53 that is opposed by heat-shock protein 90 and precedes p53 proteasomal degradation. J Biol Chem 282:14626\u201314634","journal-title":"J Biol Chem"},{"key":"9744_CR29","doi-asserted-by":"publisher","first-page":"6566","DOI":"10.1158\/0008-5472.CAN-10-0942","volume":"70","author":"J Xu","year":"2010","unstructured":"Xu J, Timares L, Heilpern C, Weng Z, Li C, Xu H, Pressey JG, Elmets CA, Kopelovich L, Athar M (2010) Targeting wild-type and mutant p53 with small molecule CP-31398 blocks the growth of rhabdomyosarcoma by inducing reactive oxygen species-dependent apoptosis. Cancer Res 70:6566\u20136576","journal-title":"Cancer Res"},{"key":"9744_CR30","doi-asserted-by":"publisher","first-page":"3342","DOI":"10.1093\/emboj\/17.12.3342","volume":"17","author":"KG McLure","year":"1998","unstructured":"McLure KG, Lee PW (1998) How p53 binds DNA as a tetramer. EMBO J 17:3342\u20133350","journal-title":"EMBO J"},{"key":"9744_CR31","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.molcel.2006.05.015","volume":"22","author":"M Kitayner","year":"2006","unstructured":"Kitayner M, Rozenberg H, Kessler N, Rabinovich D, Shaulov L, Haran TE, Shakked Z (2006) Structural basis of DNA recognition by p53 tetramers. Mol Cell 22:741\u2013753","journal-title":"Mol Cell"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-011-9744-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-011-9744-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-011-9744-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-011-9744-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:32:24Z","timestamp":1678559544000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-011-9744-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,13]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["9744"],"URL":"https:\/\/doi.org\/10.1007\/s10637-011-9744-z","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,13]]},"assertion":[{"value":"20 June 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}